Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R., AKIN S., ...Daha Fazla

JOURNAL OF BUON, cilt.21, sa.4, ss.799-808, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 4
  • Basım Tarihi: 2016
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.799-808
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose: Optimal duration of adjuvant trastuzumab therapy in early-stage HER2-positive, lymph node-negative breast cancer is unknown. To establish this, we compared 1-year and 9-week trastuzumab regimens in HER2-positive, lymph node-negative early-stage breast cancer patients.